Modulation of systemic Immune Responses by Transplantation of Hemotopoietic Stem Cells Transduced with Genes Encoding Antigens and Antigen Presenting Cell Regulatory Molecules
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cancer / autoimmune (immune tolerance modulation)
Modality
Gene Therapy
Mechanism
hematopoietic stem cell gene transduction for antigen presentation
Target
—
rNPV Envelope
Low
-$48.5M
costs +25% · peak −25%
Base
-$38.7M
cumulative PoS 0.8%
High
-$28.9M
costs −25% · peak +25%
This is an illustrative ex vivo HSC gene-therapy envelope. The actual asset is an expired platform method from 2001 with no product, so costs reflect the expensive HSC workflow while PoS is held well below approved disease-corrective HSC gene therapies.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #39 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#31) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Ex vivo antigen-encoding hematopoietic stem cell tolerance platform
The direct asset: transducing HSCs ex vivo with antigen and APC-regulatory genes to modulate systemic immune responses after transplantation.
Criteria 1: exact platform mechanism; expired IP and no single product.
Approved ex vivo HSC gene therapies (Zynteglo, Skysona, Casgevy class)
Regulatory/CMC archetype for autologous HSC collection, genetic modification, conditioning, and reinfusion. These are disease-corrective products, not antigen-tolerance platforms.
Criteria 3 and 4: same broad HSC-gene-therapy workflow, different disease biology and commercial model.
HSC gene therapy immune-tolerance literature
Adjacent field literature for immune responses to gene-modified HSCs and tolerance induction, supporting the platform concept but not a product rNPV.
Criteria 1 and 4: same immune-tolerance concept, not a clinical product comparator.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $20.0M | 30 mo | 28.0% | [0] [2] |
| Phase I | $70.0M | 24 mo | 50.0% | [1] [2] |
| Phase II | $150.0M | 36 mo | 20.0% | [1] [2] |
| Phase III | $300.0M | 48 mo | 36.0% | [1] |
| NDA/BLA Review | $18.0M | 12 mo | 82.0% | [1] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$60.0M peak · WACC 16.0%
Peak revenue. This is not a product revenue asset. The $60M illustrative peak reflects a hypothetical follow-on platform/license value if rebuilt with modern IP, not the expired JHU method itself.
WACC. Expired HSC-platform IP without a product has high commercial risk despite a validated broader HSC-gene-therapy field.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$38.7M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$143.8M
P25
-$43.8M
P50 (median)
-$19.5M
P75
-$11.8M
P95
-$6.8M
Prob ≥ 0
0.0%
Evidence register
3 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is expired ex vivo HSC antigen/transduction platform cmo_findings.asset_class_reality | Modulation of systemic Immune Responses by Transplantation of Hematopoietic Stem Cells Transduced with Genes Encoding Antigens regulatory | 2014-10-07 | high |
Approved ex vivo cell/gene therapy archetypes exist comparators[1] | Approved Cellular and Gene Therapy Products regulatory | 2026-01-01 | high |
HSC gene therapy immunology / tolerance context comparators[2] | Immunoresponse to Gene-Modified Hematopoietic Stem Cells peer_review | 2019-10-01 | high |
Thesis
Why this asset earns its rank
This is an enabling ex vivo HSC-transduction/tolerance platform, not a single therapeutic product. The JHU technology introduces antigen-encoding and APC-regulatory genes into hematopoietic stem cells ex vivo, then transplants those cells to modulate systemic immune responses. The patent is expired. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
The comparator set shows field feasibility but not asset value. Approved ex vivo HSC gene therapies validate the workflow of collection, modification, conditioning, and reinfusion, and immunology literature supports tolerance concepts, but none converts this old method into a current product. The engine result is -$48.5M to -$28.9M, with a base rNPV of -$38.7M and cumulative PoS of 0.8%; that placeholder is a conservative follow-on platform envelope, not a forecast for the expired patent.
Verdict: conceptually relevant but commercially stale. It earns its rank through gene-therapy modality scoring and immune-modulation relevance, while a CMO would ask for a modern antigen, disease, conditioning regimen, safety package, and new IP before diligence continues.
Key risks
Asset-specific, not generic biotech risks
- Expired IP: the listed US patent expired in 2022, limiting commercialization.
- Product-definition gap: no antigen, disease, vector, conditioning regimen, or patient population is specified.
- Workflow burden: ex vivo HSC therapy requires conditioning and complex manufacturing, which is hard to justify for vague immune modulation.
- Safety risk: antigen expression and APC regulation could induce unwanted immunity or tolerance depending on context.